CN102015736A - 新型{4-[2-(二甲基氨基)-1-(1-羟基环己基)乙基]苯氧基}磷酸酯或其药学上可接受的盐、其制备方法及包含上述化合物作为活性组分的、用于预防和治疗中枢神经系统疾病的药物组合物 - Google Patents

新型{4-[2-(二甲基氨基)-1-(1-羟基环己基)乙基]苯氧基}磷酸酯或其药学上可接受的盐、其制备方法及包含上述化合物作为活性组分的、用于预防和治疗中枢神经系统疾病的药物组合物 Download PDF

Info

Publication number
CN102015736A
CN102015736A CN2009801165278A CN200980116527A CN102015736A CN 102015736 A CN102015736 A CN 102015736A CN 2009801165278 A CN2009801165278 A CN 2009801165278A CN 200980116527 A CN200980116527 A CN 200980116527A CN 102015736 A CN102015736 A CN 102015736A
Authority
CN
China
Prior art keywords
dimethylamino
ethyl
disorder
nervous system
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801165278A
Other languages
English (en)
Chinese (zh)
Inventor
姜皙远
全钟洙
姜兴模
洪义释
千广宇
卞岭锡
金明华
文荣一
柳济万
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jeil Pharmaceutical Co Ltd
Original Assignee
Jeil Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jeil Pharmaceutical Co Ltd filed Critical Jeil Pharmaceutical Co Ltd
Publication of CN102015736A publication Critical patent/CN102015736A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN2009801165278A 2008-05-08 2009-05-08 新型{4-[2-(二甲基氨基)-1-(1-羟基环己基)乙基]苯氧基}磷酸酯或其药学上可接受的盐、其制备方法及包含上述化合物作为活性组分的、用于预防和治疗中枢神经系统疾病的药物组合物 Pending CN102015736A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020080043034A KR100965527B1 (ko) 2008-05-08 2008-05-08 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
KR10-2008-0043034 2008-05-08
PCT/KR2009/002426 WO2009136756A2 (ko) 2008-05-08 2009-05-08 신규 {4-[2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸]페녹시}포스페이트 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환 예방 및 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
CN102015736A true CN102015736A (zh) 2011-04-13

Family

ID=41265177

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801165278A Pending CN102015736A (zh) 2008-05-08 2009-05-08 新型{4-[2-(二甲基氨基)-1-(1-羟基环己基)乙基]苯氧基}磷酸酯或其药学上可接受的盐、其制备方法及包含上述化合物作为活性组分的、用于预防和治疗中枢神经系统疾病的药物组合物

Country Status (6)

Country Link
US (1) US8334277B2 (enExample)
EP (1) EP2287171A4 (enExample)
JP (1) JP2011519917A (enExample)
KR (1) KR100965527B1 (enExample)
CN (1) CN102015736A (enExample)
WO (1) WO2009136756A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109761826A (zh) * 2019-01-17 2019-05-17 烟台大学 一种o-去甲基文拉法辛苯醚化合物及其制备方法和用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012140577A1 (en) 2011-04-12 2012-10-18 Lupin Limited Modified release pharmaceutical compositions of desvenlafaxine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673838B2 (en) * 2001-02-12 2004-01-06 Wyeth Succinate salt of O-desmethyl-venlafaxine
US6696496B2 (en) * 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
US20070098797A1 (en) * 2005-06-02 2007-05-03 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
DE69429895T2 (de) 1993-06-28 2002-08-29 American Home Products Corp., Madison Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
US5530013A (en) 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6348494B1 (en) 2000-11-21 2002-02-19 American Home Products Corporation Ethers of o-desmethyl venlafaxine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673838B2 (en) * 2001-02-12 2004-01-06 Wyeth Succinate salt of O-desmethyl-venlafaxine
US6696496B2 (en) * 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
US20070098797A1 (en) * 2005-06-02 2007-05-03 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIC A. MUTH,ET AL.: ""Biochemical, Neurophysiological, and Behavioral Effects of Wy-45,233 and Other Identified Metabolites of the Antidepressant Venlafaxine"", 《DRUG DEVELOPMENT RESEARCH》 *
PETER ETTMAYER,ET AL.: ""Lessons Learned from Marketed and Investigational Prodrugs"", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109761826A (zh) * 2019-01-17 2019-05-17 烟台大学 一种o-去甲基文拉法辛苯醚化合物及其制备方法和用途

Also Published As

Publication number Publication date
EP2287171A2 (en) 2011-02-23
KR20090117127A (ko) 2009-11-12
JP2011519917A (ja) 2011-07-14
WO2009136756A3 (ko) 2010-02-11
WO2009136756A2 (ko) 2009-11-12
US8334277B2 (en) 2012-12-18
US20110059923A1 (en) 2011-03-10
KR100965527B1 (ko) 2010-06-23
EP2287171A4 (en) 2012-07-11

Similar Documents

Publication Publication Date Title
EP1360169B1 (en) Succinate salt of o-desmethyl-venlafaxine
US9682091B2 (en) Oral forms of a phosphonic acid derivative
AU2002250058A1 (en) Novel succinate salt of O-desmethyl-venlafaxine
JP2018516891A (ja) Ｓ−ケタミンの（ｓ）−ｃｓａ塩、ｓ−ケタミンの（ｒ）−ｃｓａ塩、及びｓ−ケタミンの調製プロセス
EA028395B1 (ru) Способы получения фенилацетата l-орнитина
JP2023551145A (ja) 医薬化合物の錯化剤塩製剤
HUE028411T2 (en) Precursors and derivatives of 6-cyclohexyl-1-hydroxy-4-methylpyridin-2 (1H) -one \ t
AU2015249065A1 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
US6187807B1 (en) Methods of use and compositions of (S) (-)-amisulpride
US20230115711A1 (en) MICROMOLECULE PI4KIIIalpha INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
CN102015736A (zh) 新型{4-[2-(二甲基氨基)-1-(1-羟基环己基)乙基]苯氧基}磷酸酯或其药学上可接受的盐、其制备方法及包含上述化合物作为活性组分的、用于预防和治疗中枢神经系统疾病的药物组合物
US20100035994A1 (en) Novel hydrate form of o-desmethyl venlafaxine succinate
US20100063160A1 (en) Polymorphs of o-desmethyl venlafaxine succinate
KR101022335B1 (ko) 신규4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시 유도체 또는 이의 약학적으로 허용가능한 염, 이의제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환예방 및 치료용 조성물
HK1057885B (en) Succinate salt of o-desmethyl-venlafaxine
AU2007203410A1 (en) Novel succinate salt of o-desmethyl-venlafaxine
HK1111679A (en) Method for preparing o-desmethyl-venlafaxine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110413